Pepex Biomedical Receives Grant Under Qualifying Therapeutic Discovery Project

Today, Pepex Biomedical, Inc. announced that the company has been awarded a grant of $244,479.25 under the Qualifying Therapeutic Discovery Project created by Congress as a component of the Patient Protection and Affordable Care Act of 2010, the major health care reform bill, signed into law by President Obama on March 23, 2010.

Pepex submitted their ground-breaking, patented, electrochemical biosensor, nanotechnology and the company received the maximum allowable grant amount.  The Pepex technology can be used in a wide array of products for more rapid diagnosis and intervention of disease which will improve patient quality-of-life and save lives.

Pepex CEO, Steve Collins said, "We are delighted to receive the grant.  These funds were awarded to a select group of companies and this represents another confirmation of Pepex' potential as a valuable contributor to the medical community, for improved patient care."

The Qualifying Therapeutic Discovery Project (QTDP) offers, at the discretion of each recipient company, either a tax credit or grant equal to eligible costs and expenses for tax years 2009 and 2010. Each grant cannot exceed $244,479.25.  The objective of the QTDP was to assist small, innovative biomedical companies with the ultimate goal of reducing long-term, healthcare costs in the United States.

The QTDP defined clear and strict submission qualifications to drive successful attainment of its goal. Only companies with less than 250 employees could submit project applications for grant consideration.  The winning group of recipients has an average number of 20 employees.  Projects submitted were required to demonstrate reasonable potential to result in new therapies for treatment of unmet medical needs in the areas of prevention and detection of chronic or acute disease.  Additional selection criteria for the awards included the likelihood for a project to create high-quality, high-paying jobs in the U.S. market and to increase U.S. competitiveness in the life science and pharmaceutical fields.  Companies were required to submit discrete applications for each project in development to the Department of Treasury.

Source: http://www.pepex.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.